A total of 19 abstracts from University of Iowa and UI Holden Comprehensive Cancer Center researchers have been accepted to the 2024 American Association of Cancer Research (AACR) Annual Meeting. The abstracts highlight research advances in several types of cancer, including endometrial, lung, colorectal and breast.

A third of the accepted abstracts include work conducted by trainees in the Cancer Biology and Free Radical and Radiation Biology Programs.

The full list of presentations at the 2024 AACR Annual Meeting is below:

1018 / 28 - Characteristics and outcomes of patients with cystic fibrosis and pancreatic cancer: A population-based comparative analysis S. Manchkanti, S. J. Gaddam2, U. S. Grewal; Joel Shilyansky

April 7, 2024, 1:30 PM - 5:00 PM | Section 41

199 / 8 - Fluid shear stress enhances metastatic potential and rapidly alters metabolism of circulating tumor cells D. L. Moose, A. N. Pope, M. Dykstra, E. B. Taylor, P. Breheny, M. D. Henry;

 April 7, 2024, 1:30 PM - 5:00 PM | Section 8

484 / 4 - Enhancing therapeutic responses in NSCLC using iron-oxide nanoparticles combined with pharmacological ascorbate M. Singhania, M. S. Petronek, C. F. Pulliam, K. A. Mapuskar, A. Zaher, D. R. Spitz;

April 7, 2024, 1:30 PM - 5:00 PM | Section 20

941 / 9 - Patient-derived model systems of endometrial cancers for disease modeling and drug sensitivity testing T. Li1, X. Huang2, R. Rosenmeyer1, S. Robinson1, K. Salsabil3, Y. Xiong1, X. Meng1, S. Yang1;

April 7, 2024, 1:30 PM - 5:00 PM | Section 39

98 / 2 - SETDB1 promotes tumorigenesis in endometrial cancer through suppressing anti-tumor immune response and increasing proliferation. K. Salari1, J. Hao1, M. Wells2, E. Johnson1, R. Jilek1, J. Gilbert1, R. Mclerran1, D. Meyerholz1, M. Yates3, B. Li1, S. Yang1;

April 7, 2024, 1:30 PM - 5:00 PM | Section 4

1998 / 14 - ABCB1 promotes uveal melanoma cell resistance to FR900359 and identifies a tumor cell subpopulation with a distinct gene expression signature S. D. Murray1, J. D. Riordan1, E. R. Anderson1, M. D. Onken2, K. J. Blumer2, A. J. Dupuy1, C. S. Stipp1;

April 8, 2024, 9:00 AM - 12:30 PM | Section 26

3224 / 8 - Identifying the molecular mechanisms underlying progesterone receptor downregulation in endometrial cancer X. Meng, L. Lamont, S. Yang;

April 8, 2024, 1:30 PM - 5:00 PM | Section 24

3578 / 7 - A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs C. G. Tran1, L. C. Borbon1, D. H. Tow1, J. Shilyansky1, G. Li1, J. Egan1, S. K. Sherman1, E. Abusada1, J. Tang2, R. govindan3, R. C. Fields3, T. A. Braun1, C. H. Chan1, C. Chandrasekharan1, D. Spitz1, D. E. Quelle1, A. M. Bellizzi1, J. R. Howe V1, P. Ear1;

April 8, 2024, 1:30 PM - 5:00 PM | Section 38             

4677 / 30 - Characterizing resistant and metastatic phenotypes to pharmacological ascorbate in pancreatic cancer A. N. Pope, B. R. O'Leary, J. Du, G. R. Buettner, M. D. Henry, J. J. Cullen;

April 9, 2024, 9:00 AM - 12:30 PM | Section 27

LB211 / 6 - Genetic complexity in OSCC metastasis: From transcription factors to novel therapeutic targets G. Flores, S. Uaroon, M. Buchakjian;

April 8, 2024, 1:30 PM - 5:00 PM | Section 54

4466 / 20 - Omega-3 fatty acid-induced ferroptosis in 4T1 breast cancer through CD36/FABP5 axis 

A. Avellino, J. Hao, M. Yorek, J. Yu, B. Li;

April 9, 2024, 9:00 AM - 12:30 PM | Section 19

4616 / 14 - TBK1 and GSK3 mediated TRAF2 phosphorylation confers resistance to PI3K-AKT inhibition in breast cancer cells H. Habelhah, L. Zhang;

April 9, 2024, 9:00 AM - 12:30 PM | Section 25

5425 / 19 - MITF/TFE regulatory programs in neural crest migration are co-opted in melanoma metastasis J. Chang1, K. Campbell1, R. Moore1, R. Cornell2, C. Kenny1;

April 9, 2024, 1:30 PM - 5:00 PM | Section 7

5647 / 26 - Investigating the role of AP-2α in melanomagenesis N. Bartschat, J. Chang, M. Suraju, R. Nagel, Z. Li, J. White, C. Kenny, R. Weigel

 April 9, 2024, 1:30 PM - 5:00 PM | Section 15

5852 / 28 - Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia J. Raygoza Garay1, S. Yun2, A. Osman3, R. Ramlal4, D. Feith5, M. Churchman6, P. Dhakal1;

April 9, 2024, 1:30 PM - 5:00 PM | Section 23

5910 / 24 - Developing a novel humanized anti-FABP4 antibody for breast cancer treatment J. Hao, M. Yorek, J. Yu, A. Avellino, B. Li;

April 9, 2024, 1:30 PM - 5:00 PM | Section 25

6471 / 18 - Trends in chemotherapy utilization in acute myeloid leukemia (AML) in last 15 years P. Dhakal1, B. Loeffler1, A. Ravindra1, A. Pyakuryal2, V. R. Bhatt3;

April 9, 2024, 1:30 PM - 5:00 PM| Section 45

6605 - Understanding the role of sumoylated Etv1 in mammary oncogenesis Z. Li1, K. E. Koch2, D. T. Thompson1, D. M. Van der Heide1, J. Chang1, C. M. Franke1, M. O. Suraju1, A. C. Beck3, A. W. Lorenzen1, J. R. White1, M. V. Kulak1, D. K. Meyerholz1, C. Kenny1, R. J. Weigel1;

 April 9, 2024, 4:05 PM - 4:20 PM | Room 31 - Upper Level - Convention Center

7615 / 9 - Epithelial-mesenchymal-transition gene signature changes and poor oncological outcome in Candida-positive pancreatic ductal adenocarcinoma P. Ear1, M. Hu2, J. S. Shilyansky1, N. H. Fei1, S. Coleman2, R. Hoyd3, C. E. Wheeler3, K. L. Steckly1, M. L. Churchman4, N. Denko5, R. D. Dodd1, S. Hardikar2, N. Jin3, Q. Ma6, M. D. McCarter7, A. Naqash8, A. E. G. Osman9, G. Riedlinger10, L. A. Robinson11, B. P. Schneider12, E. A. Singer3, A. A. Tarhini11, G. Tinoco3, C. M. Ulrich2, Y. Zakharia1, D. Spakowicz3, A. Tan2, C. H. F. Chan1;

April 10, 2024, 9:00 AM - 12:30 PM | Section 45